Alkylating Drug class drugs

6 results

  • Bendeka

    (bendamustine hydrochloride)
    Teva Pharmaceuticals USA, Inc.
    Usage: BENDEKA® is indicated for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of rituximab treatment. Efficacy compared to first-line therapies other than chlorambucil is not established.

  • Gliadel

    (carmustine)
    Arbor Pharmaceuticals
    Usage: GLIADEL Wafer is indicated for treating newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and for recurrent glioblastoma as an adjunct to surgery.

  • Jelmyto

    (mitomycin)
    UroGen Pharma, Inc.
    Usage: JELMYTO® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).

  • Valchlor

    (mechlorethamine hydrochloride)
    Helsinn Therapeutics (U.S.), Inc.
    Usage: VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have previously undergone skin-directed therapy.

  • Yondelis

    (Trabectedin)
    Janssen Products, LP
    Usage: YONDELIS® is indicated for treating patients with unresectable or metastatic liposarcoma or leiomyosarcoma who have previously received an anthracycline-containing regimen.

  • Zepzelca

    (Lurbinectedin)
    Jazz Pharmaceuticals, Inc.
    Usage: ZEPZELCA is indicated for adult patients with metastatic small cell lung cancer (SCLC) who have disease progression following platinum-based chemotherapy. This approval is based on overall response rate and duration of response, with continued approval dependent on further confirmatory trials.